Blue Note Therapeutics develops prescription digital therapeutics focused exclusively on patients suffering from cancer, aiming to reduce anxiety, depression, and other cancer-related distress. The company is building a pipeline of clinically validated prescription digital therapeutics in collaboration with cancer research and patient communities. Led by CEO Geoffrey Eich and based in San Francisco, Blue Note emphasizes evidence-based therapeutic development. Recent financing will strengthen the company’s capacity to advance its therapeutic pipeline. The company’s core product strategy centers on clinically validated digital interventions tailored to cancer patients. Blue Note Therapeutics is a prescription digital therapeutics company focused on treating cancer-related distress, anxiety, and depression. Its lead product, BNT001, has received FDA Breakthrough Device Designation (June 2020) but is not cleared by the FDA. The company also launched a COVID Cancer Care digital wellness program in 2020 to help adults with cancer cope with pandemic-related stress. Blue Note holds licensing agreements with several leading cancer centers and universities, including the University of Miami, Massachusetts General Hospital, and Memorial Sloan Kettering Cancer Center, to digitize evidence-based, cancer-specific therapies. Proceeds from the Series A will be used to scale the organization and fund near-term clinical trials of its lead prescription digital therapeutic and to support development of its pipeline assets. The company emphasizes expanding access to evidence-based, cancer-specific mental health treatments.

Total raised

$31M

Funding rounds

2

Latest round

Series A

Latest activity

Sep 2021